Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Amgen Inc (NASDAQ: AMGN) | Delayed: 438.34 -0.6 (0.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $438.94 | 52 Week High | $176.85 | |||
| Open | $440.21 | 52 Week Low | $133.64 | |||
| Day High | $441.03 | P/E | 66.02 | |||
| Day Low | $434.53 | EPS | $6.64 | |||
| Volume | 2,610,616 | |||||
